WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2007/092772    International Application No.:    PCT/US2007/061544
Publication Date: 16.08.2007 International Filing Date: 02.02.2007
A61K 39/395 (2006.01), C07K 16/00 (2006.01)
Applicants: MEDIMMUNE, INC. [US/US]; One Medimmune Way, Legal Affairs, Gaithersburg, Maryland 20878 (US) (For All Designated States Except US).
ALLAN, Christian [US/US]; (US) (For US Only).
LEACH, William [US/US]; (US) (For US Only).
CHANG, Stephen [US/US]; (US) (For US Only).
BISHOP, Steven [US/US]; (US) (For US Only)
Inventors: ALLAN, Christian; (US).
LEACH, William; (US).
CHANG, Stephen; (US).
BISHOP, Steven; (US)
Agent: KREPPEL, Lisa; One Medimmune Way, Legal Affairs, Gaithersburg, Maryland 20878 (US)
Priority Data:
60/764,750 03.02.2006 US
60/825,231 11.09.2006 US
Abstract: front page image
(EN)The present invention provides formulations of proteins comprising a variant Fc region that improve the stability in part by reducing the propensisty of such molecules to rapidly aggregate. The invention provides both liquid and lyophilized formulations either of which can be utilized to generate a high protein concentration liquid suitable for administration to a subject. The invention further provides methods of utilizing the formulations of the present invention for therapeutic or prophylactic treatment of diseases and disorders or for diagnostic purposes.
(FR)La présente invention concerne des formulations de protéines comprenant une région Fc variante, ces formulations améliorant la stabilité en partie grâce à une réduction de la propension de ces molécules à s'agréger rapidement. L'invention concerne aussi bien des formulations liquides que des formulations lyophilisées, chacune de ces formulations pouvant être utilisée pour produire un liquide à forte concentration en protéines pouvant être administré à un sujet. L'invention concerne en outre des méthodes d'utilisation de ces formulations pour le traitement thérapeutique ou prophylactique de maladies et de troubles ou à des fins diagnostiques.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)